IDEAYA Biosciences Salute del bilancio

Salute finanziaria criteri di controllo 6/6

IDEAYA Biosciences ha un patrimonio netto totale di $1.2B e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $1.2B e $59.5M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$920.03m
Patrimonio netto	US$1.18b
Totale passività	US$59.46m
Totale attività	US$1.24b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $932.2M ) di 30J superano le sue passività a breve termine ( $40.7M ).

Passività a lungo termine: Le attività a breve termine di 30J ( $932.2M ) superano le sue passività a lungo termine ( $18.8M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: 30J è esente da debiti.

Riduzione del debito: 30J non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: 30J ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: 30J ha una liquidità sufficiente per più di 3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 33.2 % ogni anno

IDEAYA Biosciences Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

New minor risk - Revenue size

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Full year 2023 earnings released: US$1.96 loss per share (vs US$1.42 loss in FY 2022)

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.04 profit in 3Q 2022)

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

New minor risk - Share price stability

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.50 loss per share (vs US$0.57 loss in 2Q 2022)

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

New major risk - Shareholder dilution

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.36 loss in 1Q 2022)

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.41 loss in FY 2021)

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

Third quarter 2022 earnings released: EPS: US$0.04 (vs US$0.31 loss in 3Q 2021)

IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

IDEAYA Biosciences, Inc. Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-In-Class Pol Theta Helicase Inhibitor Development Candidate

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.33 loss in 2Q 2021)

IDEAYA Biosciences, Inc. Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

IDEAYA Biosciences, Inc. Announces Development Candidate Nomination of Potential First-In-Class Pol Theta Helicase Inhibitor in Collaboration with GSK

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 2000 Growth Index

IDEAYA Biosciences, Inc. Appoints Catherine Mackey to its Board of Directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IDEAYA Biosciences, Inc. Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License

IDEAYA Biosciences, Inc. Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma

Director Yujiro Hata has joined 3rd company board

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

New 90-day high: €17.80

IDEAYA Biosciences, Inc. Appoints Susan L. Kelley to its Board of Directors

New 90-day high: €16.40

IDEAYA Biosciences, Inc. Announces Appointment of Matthew Maurer as Head of Clinical Oncology and Medical Affairs

New 90-day high: €16.30

Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry

IDEAYA Biosciences, Inc. Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

New 90-day low: €10.10

Nasdaq Biotechnology Index Selects IDEAYA Biosciences, Inc

New 90-day high: €12.70

IDEAYA Biosciences, Inc. and Pfizer Inc. Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations

IDEAYA Biosciences, Inc. Names Garret Hampton to the Nominating and Corporate Governance Committee

IDEAYA Biosciences, Inc. announced that it has received $19.999995 million in funding from Glaxosmithkline Intellectual Property (No.4) Limited

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane